Every material Form 8-K Bio-Techne filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bio-Techne's board declared a $0.08 per share cash dividend for the quarter ended September 30, 2026. The payment is conditional on the pending transaction with Merck KGaA, Darmstadt, Germany not closing on or before the November 13, 2026 record date, so the dividend tie-in to that deal matters to shareholders.
Dividend of $0.08 per share for the quarter ended September 30, 2026
Payable November 23, 2026 to common shareholders of record at close of business November 13, 2026
Dividend applies only if the Merck KGaA transaction has not closed on or before November 13, 2026
Future dividends will be considered by the Board on a quarterly basis
Bio-Techne reported fourth-quarter fiscal 2026 revenue of $321.2 million, up 1% as reported and 3% organic, with GAAP EPS of $0.35 versus a loss of $0.11 a year earlier. Adjusted EPS was $0.52, down from $0.53, and full-year adjusted EPS rose to $1.93 from $1.92 on flat revenue of $1.2 billion. The company said it will no longer hold quarterly investor calls because of its pending acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share in cash.
Q4 fiscal 2026 net sales were $321.2 million, up 1% reported and 3% organic.
Q4 GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52 versus $0.53.
Full-year fiscal 2026 net sales were flat at $1.2 billion; full-year adjusted EPS was $1.93 versus $1.92.
Board declared an $0.08 per share dividend, payable September 4, 2026, to holders of record on August 24, 2026.
Bio-Techne entered a merger agreement under which Merck KGaA's subsidiary will merge into the company, leaving Bio-Techne as a wholly-owned Merck KGaA subsidiary. Each share will convert into the right to receive $73.00 in cash, and the board has recommended that shareholders approve the deal.
Merger consideration: $73.00 in cash per share of common stock, less any required tax withholdings
Buyer: Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings NewCo, Inc.
Closing requires majority shareholder approval, expiration of the Hart-Scott-Rodino waiting period and other required approvals, and no Burdensome Condition
Bio-Techne reported third-quarter fiscal 2026 results for the quarter ended March 31, 2026, with net sales down 2% to $311.4 million. GAAP diluted EPS rose to $0.32 from $0.14, but adjusted diluted EPS fell to $0.53 from $0.56, and the company said demand from biotech customers has not yet broadly recovered. The company also declared a quarterly dividend of $0.08 per share.
Net sales fell 2% to $311.4 million; organic revenue also fell 2%, with foreign exchange adding 2%.
GAAP diluted EPS was $0.32 versus $0.14; GAAP operating income rose 95% to $75.5 million.
Adjusted diluted EPS was $0.53 versus $0.56, and adjusted operating margin was 34.2% versus 34.9%.
Dividend of $0.08 per share is payable May 29, 2026, to shareholders of record on May 18, 2026.
Bio-Techne said Dr. Matt McManus is transitioning from his role as president of the Diagnostics and Spatial Biology segment, and Steve Crouse, currently senior vice president of the Analytical Solutions Division, will take over that role effective March 1, 2026. The filing also discloses Crouse's employment terms, including a $505,000 base salary and a 75% target cash bonus, and that the board terminated McManus's employment without cause on February 9, 2026. The change is a leadership transition at a segment level and does not include any reported financial results.
Steve Crouse appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
Crouse's employment agreement, dated February 10, 2026, sets a $505,000 annual base salary and a target annual cash bonus of 75% of base salary
Crouse's one-time equity awards include $85,000 at target in performance-based RSUs, plus stock options and time-vested RSUs with grant date values of approximately $42,500 each
Dr. Matt McManus's employment was terminated without cause by board approval on February 9, 2026; he is eligible for severance and will remain to support the transition
Bio-Techne reported fiscal second-quarter results for the three months ended December 31, 2025, with revenue flat at $295.9 million and GAAP operating income up 15% to $54.5 million. Adjusted EPS rose to $0.46 from $0.42, and the company also declared an $0.08 per share quarterly dividend.
Revenue was $295.9 million, flat versus the prior year, with foreign currency adding 2% and a held-for-sale business reducing revenue by 2%.
GAAP EPS was $0.24 versus $0.22; adjusted EPS was $0.46 versus $0.42.
Adjusted operating margin was 31.1% versus 30.1%, and GAAP operating income rose to $54.5 million from $47.4 million.
The $0.08 per share dividend is payable February 27, 2026, to shareholders of record on February 16, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bio-Techne filing is on SEC EDGAR ↗. 8-K briefs of other companies →